Evaluating T3 as a treatment for medulloblastoma in children
Official title: Assessment of Efficacy and Toxicity of T3 for Medulloblastoma Treatment
Funded at Research Inst of Fox Chase Can Ctr · NIH-11034598 · Data updated 2026-11-12
This study is looking at whether a thyroid hormone called T3 can help treat medulloblastoma, a common brain tumor in kids, by seeing how it works alongside regular treatments like chemotherapy and radiation, with hopes of finding safer and better options for young patients in the future.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Research Inst of Fox Chase Can Ctr NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | February 1, 2025 |
| Project end | January 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $219,351 |
| NIH project number | 1R21CA296696-01 |
| Project ID | NIH-11034598 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children under 10 years old diagnosed with medulloblastoma.
✕Less likely to help
Patients with medulloblastoma who are older than 10 years or those who have already undergone extensive treatment may not benefit from this research.
What this research studies
This research investigates the use of T3, an FDA-approved thyroid hormone, as a potential treatment for medulloblastoma, the most common malignant brain tumor in children. The study aims to assess the safety and effectiveness of T3 in combination with traditional therapies like chemotherapy and radiation. By conducting experiments in mice, the researchers will evaluate how T3 affects tumor growth and its side effects, with the goal of providing essential data for future clinical trials in children. If successful, this research could lead to improved treatment options that minimize long-term side effects for young patients.
Why it matters
Potential benefit: If successful, this research could provide a safer and more effective treatment option for children with medulloblastoma, potentially reducing long-term side effects associated with current therapies.
How similar studies have gone: While the use of T3 in this context is novel, previous studies have shown promise in using similar approaches for other types of cancers.
Where this research is happening
-
Research Inst of Fox Chase Can Ctr
Philadelphia, United States Active
Researchers
- Principal investigator: Yang, Zeng-Jie — Research Inst of Fox Chase Can Ctr
- Study coordinator: Yang, Zeng-Jie
Related research
Other NIH-funded projects on the same topics.
-
Glial origins and signaling in childhood brain cancer (medulloblastoma)
A new study looks at how glial cells may drive relapse and growth in childhood medulloblastoma, with the goal of finding targeted treatments.
-
Next generation GPC2 CARs to treat pediatric medulloblastoma
A new CAR T-cell therapy approach targets a protein common on child brain tumor cells to improve outcomes for kids with medulloblastoma.
-
Targeting medulloblastoma with multispecific T-cell engagers
A pediatric brain cancer treatment study tests a new multi-targeted T-cell engager designed to reach brain tumors and help the immune system kill cancer cells.
-
Efflux-aware brain barrier model to guide pediatric medulloblastoma drug discovery
A study using a pediatric brain cancer model to test how radiation-activated digoxin-like compounds could safely reach brain tumors in children.
-
Overcoming medulloblastoma resistance in kids using in vivo perturb-seq and preclinical therapies
A patient-focused study aiming to find new, less toxic ways to treat pediatric medulloblastoma by using advanced genetic screening to identify effective drug targets in preclinical models.
-
Dysregulation of a key gene complex and its role in Group 4 medulloblastoma
A study explores how disruption of a core gene complex in brain development may drive Group 4 medulloblastoma and seeks to understand new ways to help affected children.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.